These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1725038)

  • 1. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction.
    Schölkens BA; Linz W; Martorana PA
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S26-30. PubMed ID: 1725038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W; Martorana PA; Schölkens BA
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.
    Martorana PA; Schölkens BA
    Agents Actions Suppl; 1992; 38 ( Pt 3)():98-102. PubMed ID: 1462888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].
    Schölkens BA; Linz W
    Klin Wochenschr; 1991; 69 Suppl 24():1-5. PubMed ID: 1865630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interference with the cardiac renin-angiotensin system.
    Becker RH; Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S10-5. PubMed ID: 2483422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
    Linz W; Gohlke P; Unger T; Schölkens BA
    Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():31-4. PubMed ID: 7646309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
    Gohlke P; Linz W; Schölkens B; Van Even P; Martorana P; Unger T
    Br J Clin Pract Suppl; 1996 Jul; 84():1-10. PubMed ID: 8994995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
    Schölkens BA; Linz W
    Clin Physiol Biochem; 1990; 8 Suppl 1():33-43. PubMed ID: 2147878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.
    Hartman JC; Kurc GM; Hullinger TG; Wall TM; Sheehy RM; Shebuski RJ
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1071-6. PubMed ID: 7523655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():53-6. PubMed ID: 7856280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reduction of infarct size and remodeling after ramipril].
    Martorana PA; Linz W; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():63-4. PubMed ID: 7856282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
    Schriefer JA; Broudy EP; Hassen AH
    J Pharmacol Exp Ther; 2001 Sep; 298(3):970-5. PubMed ID: 11504792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
    Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
    Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
    Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
    J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective potential of angiotensin-converting enzyme inhibitors.
    Gavras I; Gavras H
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV68-71; discussion IV83-90. PubMed ID: 1893645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
    Mervaala EM; Malmberg L; Teräväinen TL; Laakso J; Vapaatalo H; Karppanen H
    Br J Pharmacol; 1998 Jan; 123(2):195-204. PubMed ID: 9489606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.
    Linz W; Schölkens BA; Ganten D
    Clin Exp Hypertens A; 1989; 11(7):1325-50. PubMed ID: 2530011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
    Hartman JC; Wall TM; Hullinger TG; Shebuski RJ
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):996-1003. PubMed ID: 7687728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.